Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LVGN6051 |
Synonyms | |
Therapy Description |
LVGN6051 is a monoclonal antibody that targets 4-1BB (CD137) and acts as an agonist in the presence of Fc-gammaRIIB, potentially resulting in decreased tumor growth (PMID: 31105267). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LVGN6051 | LVGN-6051|LVGN 6051|Exlinkibart | TNFRSF9 Antibody 32 | LVGN6051 is a monoclonal antibody that targets 4-1BB (CD137) and acts as an agonist in the presence of Fc-gammaRIIB, potentially resulting in decreased tumor growth (PMID: 31105267). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04130542 | Phase I | LVGN6051 | Phase 1 Trial of LVGN6051 as Single Agent and in Combination Therapy in Advanced or Metastatic Malignancy | Active, not recruiting | USA | 0 |